Advances in the application of mepolizumab in the treatment of FIP1L1-PDGFRα-negative hypereosinophilic syndrome
Hypereosinophilic syndrome(HES)is a rare hematological disease characterized by persistent eosinophilia in the peripheral blood and eosinophil-mediated damage to target organs.The primary goal of treatment is to reduce the long-term levels of eosinophils in tissues or blood,and to prevent or reverse its damage in tissues and organs.Mepolizumab has been shown to significantly decrease the frequency of HES flares and lower eosinophil levels in tissues and blood.It has been approved by the FDA for use in fip1-like 1-platelet-derived growth factor receptor alpha(FIP1L1-PDGFRα)-negative HES.This article reviews the current status of mepolizumab in the treatment of FIP1L1-PDGFRα-negative HES..
万方数据
维普
